Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication.
about
In vivo magnetic enrichment, photoacoustic diagnosis, and photothermal purging of infected blood using multifunctional gold and magnetic nanoparticlesA functionalized surface modification with vanadium nanoparticles of various valences against implant-associated bloodstream infectionNitropropenyl benzodioxole, an anti-infective agent with action as a protein tyrosine phosphatase inhibitorBiosensor diagnosis of urinary tract infections: a path to better treatment?Nitric oxide nanoparticles: pre-clinical utility as a therapeutic for intramuscular abscesses.Excess deaths associated with tigecycline after approval based on noninferiority trials.Targeting iron assimilation to develop new antibacterials.Effect of Relative Arrangement of Cationic and Lipophilic Moieties on Hemolytic and Antibacterial Activities of PEGylated Polyacrylates.β-Lactam Antibiotics Renaissance.Recurrent Challenges for Clinicians: Emergence of Methicillin-Resistant Staphylococcus aureus, Vancomycin Resistance, and Current Treatment Options.Emerging gram-negative infections in burn wounds.Surveillance and management of multidrug-resistant microorganisms.The enhanced permeability retention effect: a new paradigm for drug targeting in infection.Peptides as the next generation of anti-infectives.Nanosilver-based antibacterial drugs and devices: mechanisms, methodological drawbacks, and guidelines.Antifungal stewardship in daily practice and health economic implications.Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials.Identification and structural characterization of LytU, a unique peptidoglycan endopeptidase from the lysostaphin family.Functional polypyrrole-silica composites as photothermal agents for targeted killing of bacteria.
P2860
Q27317464-FC7B1BED-80E3-42A9-B937-26DB785C8095Q33596392-7BE92233-17EB-438F-AD33-10A8DFE26374Q33815443-A7AC6A2F-E87C-430A-9F9C-70960BA87FF5Q35019487-943BFC99-4467-45EE-BA66-B0EE734A2A0FQ35914150-13EA6705-7BC2-410F-86CD-829D5D60B423Q36115632-160CB267-41AC-44C5-96A1-4596EC4CD70CQ36211648-A3EA1FD4-B9FD-46F6-A5E2-14A534473D9BQ36247341-78BB728B-7243-4109-A24E-4943B728ED95Q36683689-9C1E5DEF-B99D-4EEA-8047-22F8C1FB48AEQ37670551-7BBE4D83-ECA4-4DAF-BFDB-775A296E36F3Q37906181-0157E5E2-3F97-4ED1-9ED8-853ABFAEACC4Q37912231-05BDE2D1-AE25-49E1-A514-F810E074FBC0Q38051263-CFCC5FD6-A060-4B71-A3DF-76282C322B32Q38086871-A5FC71CE-1CE3-4D96-A88C-45884AB0414EQ38167600-F75B5D48-9C75-489C-826D-0B084AFBCF1FQ38511950-12ABE6FA-2D88-4E80-8CCC-97CC0E8C7E48Q38741713-9B444F0E-0043-40B4-8C79-12ED5B51139AQ40125665-63FA36D4-7975-4FF2-ADC1-18E284D8F9B9Q43713283-14AE81B4-3194-479B-9E20-11806DB65C11
P2860
Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Challenges in anti-infective d ...... am infection as an indication.
@en
Challenges in anti-infective d ...... am infection as an indication.
@nl
type
label
Challenges in anti-infective d ...... am infection as an indication.
@en
Challenges in anti-infective d ...... am infection as an indication.
@nl
prefLabel
Challenges in anti-infective d ...... am infection as an indication.
@en
Challenges in anti-infective d ...... am infection as an indication.
@nl
P356
P1476
Challenges in anti-infective d ...... am infection as an indication.
@en
P2093
Helen W Boucher
P356
10.1086/647937
P407
P478
50 Suppl 1
P577
2010-01-01T00:00:00Z